In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
|Articles|January 29, 2021
The COVID-19 Pandemic Has Disrupted Cancer Trials
Author(s)Aislinn Antrim, Assistant Editor
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.
Advertisement
Pharmacy Times® interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers and medical director at Ann B. Barshinger Cancer Institute, Penn Medicine in Lancaster PA about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trial.
The full conversation can be found in the video above.
Advertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
Pneumonic Plague: What Pharmacists Need to Know About Treatment
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5